Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized Controlled Study on the Efficacy and Safety of Venetoclax Combined With 3-Day Decitabine (DEC3-VEN) Versus Venetoclax Combined With "2+6" DA Versus "3+7" DA Regimen in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT07712848 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Kunming Medical University as lead sponsor.

NCT NCT07712848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07712848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized Controlled Study on the Efficacy and Safety of Venetoclax Combined With 3-Day Decitabine (DEC3-VEN) Versus Venetoclax Combined With "2+6" DA Versus "3+7" DA Regimen in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia
Lead sponsor
The Second Affiliated Hospital of Kunming Medical University
Phase
Phase 3
Overall status
Recruiting
Start date
April 1, 2026
Completion date
December 1, 2027
Enrollment
291 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml (acute myeloid leukemia)